QPPV.COM KNOWLEDGE ASSESSMENT

Garadacimab: Mechanism, Clinical Use and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Garadacimab: FXIIa Inhibition, Hereditary Angioedema and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should a case-processing record include rescue medicines and other preventive HAE therapies?
Question 2 of 10 Which statement best reflects the significance of HAE subtype when assessing garadacimab response?
Question 3 of 10 Which description best distinguishes garadacimab’s pharmacological action from other HAE treatment approaches?
Question 4 of 10 A swelling episode occurs during garadacimab treatment, but the report lacks enough detail to distinguish HAE from an allergic reaction. What is the best follow-up approach?
Question 5 of 10 A patient has one well-documented HAE attack after starting prophylaxis. Which interpretation is most appropriate?
Question 6 of 10 Why is baseline attack frequency and severity important when evaluating response after garadacimab initiation?
Question 7 of 10 A team is evaluating an apparent increase in reports of breakthrough attacks over time. Which analysis plan is most consistent with the article?
Question 8 of 10 Why should a case report record the actual injection date rather than only the scheduled due date?
Question 9 of 10 A patient experiences repeated severe attacks despite documented injections. Which approach best evaluates whether this represents inadequate preventive response?
Question 10 of 10 A signal review raises the possibility of loss of effect in some patients. How should the team communicate this finding before causality is established?

Select an answer to continue.

QPPV.com